Program notes:

0:40 CVD risk factors and texting

1:40 How many undergo screening?

2:41 Impact of personalized messaging

3:25 Decentralized trials versus centralized 

4:25 Decentralized much larger

5:25 Does the trial move in one way or another?

6:15 Two studies related to use of peripregnancy GLP-1 use

7:15 Stopping at pregnancy

8:15 Is overweight worse than stopping?

9:00 Machine learning model, tissues, genetics and age

10:00 Practical for assessing genetic basis

11:00 Sequential tissue samples

11:57 End